Table 2 Application of siRNA and chemotherapeutics combination strategies in the therapy of pancreatic cancer
From: Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
S.No. | Nanocarrier/ Other type of Carrier | Targeting ligand | In vivo model | Route of administration | Combination | Cell line | Result | Ref. |
|---|---|---|---|---|---|---|---|---|
1. | Lipid NP | HIFIα | Mouse | Intravenous | siRNA and GEM | Panc-1 | Prevention in burst release and boosted cytoxicity of GEM | [113] |
2. | Lipid NP | HIFIα | Mouse | Intravenous | siRNA and GEM | Panc-1 | Increased intracellular concentration and reduction in tumour weight | [114] |
3. | Lipid NP | KRAS | Mouse | Intravenous | siRNA and GEM | Panc-1 | Decreased tumour proliferation, enhanced apoptosis and no toxicity | [115] |
4. | Lipid NP | Mcl-1 | Mouse | Intravenous | siRNA and GEM | BxPC3 and Panc-1 | Higher cellular uptake, prevention of siRNA from nuclease degradation and overcomes GEM resistance | [116] |
5. | Lipid NP | RRM2 | Mouse | Intraperitoneal and Peritumoral | siRNA and DOX | Panc-1 | Reduction in tumour growth, decreased metastasis and DOX dose | [117] |
6. | Polymer NP | PLK 1 | Mouse | Intraperitoneal | siRNA and GEM | KPC8060 and S2–013 | Greater accumulation in tumours and significant increase in anti-cancer activity | [118] |
7. | Dendrimer | ITCH | Mouse | Subcutaneous | siRNA and GEM | Mia-PaCa-2, BxPC3 and Panc-1 | Significant gene knockdown and increased chemo sensitivity | [43] |
8. | Gold NP | KRAS | Mouse | Intratumoral | siRNA and DOX | Panc-1 | Reduction in tumour growth by 90% | [119] |
9. | Magnetic NP | PD-L1 | Mouse | Intravenous | siRNA and GEM | PAN-02 | Supressed tumour growth and improved survival rates | [120] |
10. | Implant | KRAS | Mouse and Human Patients | Subcutaneous | siRNA and GEM | – | Sustained release of drug, prevention of siRNA from serum degradation and enhanced overall survival rates | [121] |
11. | Biodegradable construct | CHK1 | – | – | siRNA and GEM | Mia-PaCa-2, BxPC3,Panc-1 and CEPAC-1 | Reduction in GEM dose and enhanced efficacy | [122] |
12. | Polyester based vectors | Notch-1 and KRAS | – | – | siRNA and GEM | Mia-PaCa-2 | Increased apoptosis and chemo sensitivity | [123] |